How to Reconstitute Semaglutide — and Why Licensed Wegovy Doesn't Require It

Why reconstitution guides exist, and what they are really describing

The reconstitution question has a specific origin. Semaglutide is also synthesised and sold as a raw peptide (often labelled for "research use only") by suppliers operating outside the regulated medicines supply chain. These products typically arrive as a white lyophilised powder in a vial, and buyers are instructed to add bacteriostatic water or another reconstitution solution to create an injectable liquid. That process of mixing the powder with liquid is what "reconstituting semaglutide" means in practice.

None of those products are the same thing as Wegovy. The NHS medicines page for semaglutide describes Wegovy as a pre-filled, single-use pen containing a ready-to-inject solution, no preparation step, no syringe drawing, no concentration calculation. The only thing you do before injecting is check the liquid is clear, attach a needle, select the dose dial if applicable, and follow the Patient Information Leaflet supplied with your prescription.

For anyone curious about the specific process of reconstituting a 2mg semaglutide vial, there is a dedicated page covering that topic in full, including why that concentration figure appears and where the practice comes from. The short version: it is not a step in licensed Wegovy use.

What the clinical evidence was built on, and why that matters for reconstituted products

The weight-loss evidence for semaglutide comes from trials using the licensed formulation, at precise, validated doses, manufactured under pharmaceutical-grade conditions. The STEP 1 trial (published in the New England Journal of Medicine) enrolled adults with obesity or overweight and a weight-related condition, finding an average body-weight reduction of around 15% over 68 weeks at the 2.4mg weekly maintenance dose. That result is a product of a specific molecule, a specific formulation, and a specific dosing schedule reviewed by a prescriber throughout.

Reconstituted peptide vials introduce variables that the clinical trials never tested: concentration accuracy (a home reconstitution that is 10% off produces a meaningfully different dose), sterility (lyophilised peptides require careful handling and storage), and the absence of any prescriber reviewing what you are taking. If you want to understand the broader semaglutide landscape (licensed versus unlicensed, injection versus tablet) the semaglutide overview page pulls it together clearly.

The MHRA has been direct on this point. Its public guidance on GLP-1 medicines warns that unlicensed versions sold online, including those requiring reconstitution, have not been assessed for quality, safety or efficacy. Enforcement action through 2024 and 2025 resulted in approximately 20 million doses of illegally traded weight-loss medicines being seized, with a street value around £45 million, including the first UK site found manufacturing counterfeit tirzepatide pens. The same supply chains that sell counterfeit pens also supply unlicensed peptide vials.

Reconstitution calculations, and why they carry real risk without clinical oversight

One of the most searched adjacent questions is how much reconstitution solution to add to a given amount of powdered semaglutide to reach a target concentration. A semaglutide reconstitution calculator can walk through the maths, but the calculation itself illustrates the problem. If someone intends to inject 0.25mg per dose from a 2mg vial, they need to add precisely the right volume of bacteriostatic water and then draw exactly the right volume into a syringe. A measurement error of a fraction of a millilitre shifts the dose materially. Do this without a prescriber, without pharmaceutical manufacturing standards, and without any verification of the starting material's actual purity, and the risk is not theoretical.

For people who have been using a compounded or unlicensed product and are looking for a licensed alternative, the semaglutide substitute page explains the options available in the UK, including Wegovy and the newly approved Wegovy tablet. A prescriber at a regulated service can review your current situation and assess which licensed treatment, if any, suits you, without you needing to bring your own vials or calculate your own doses.

If you are trying to make sense of what the mixing process actually involves before deciding whether a licensed pen is the right step, the page on mixing semaglutide with reconstitution solution covers the practical steps honestly, alongside the safety context. Worth reading before drawing any conclusions.

Getting licensed semaglutide legally, what the process looks like

Wegovy is a Prescription-Only Medicine. The only legal route to it in the UK is a prescription issued following a clinical assessment by a qualified prescriber. That is not a bureaucratic inconvenience; it is the mechanism that ensures the dose you receive is appropriate for your health profile, your other medicines, and your weight-management goals.

At a regulated service like ours, the process runs roughly like this: you complete a consultation, a GPhC-registered prescriber reads your answers the same day, your identity and weight are verified, and (if clinically suitable) your prescription is dispensed and sent out via tracked next-working-day delivery. No reconstitution. No vials. No syringes measured out on a kitchen worktop before the school run. Just a pen that arrives ready to use, with a Patient Information Leaflet that tells you exactly what to do.

For a full overview of how Wegovy works as a licensed treatment (including the dose schedule, eligibility criteria, and what to expect from the titration period) the Wegovy treatment page covers it in detail. And if you are ready to find out whether you are eligible, starting a free consultation is the straightforward next step.